DUBLIN--(BUSINESS WIRE)--May 16, 2018--The "Immuno-oncology Therapy Market by Therapy Type and by Therapeutic Areas, for Hospitals, Clinics and Cancer Research Institutes: Global Industry Perspective, Comprehensive Analysis and Forecast, 2016 - 2022" report has been added to ResearchAndMarkets.com's offering.

The study provides a decisive view on the immuno-oncology therapy market by segmenting the market based on therapy type, therapeutic area, end-user, and regions. All the segments have been analyzed based on present and future trends and the market is estimated from 2016 to 2022.

Scope of the Report

Based on therapy type the market is segmented into monoclonal antibodies, immune checkpoint inhibitors (PD1/ PDL1 and CTLA-4), immune system modulators, cancer vaccines and others. Based on the therapeutic area the market is segmented into lung cancer, colorectal cancer, breast cancer, prostate cancer, melanoma, blood cancer and other cancers. Key end-users covered under this study include hospitals, clinics, ASCs and cancer research institutes. This segmentation includes demand for immuno-oncology therapy market based on individual therapy type, therapeutic area and end-users in all the regions and countries.

Market Dynamics

Market Drivers

Highly Promising Treatment Pipeline Increase in Number of Patients Suffering from Various Cancers Greater Efficiency Over Conventional Treatment Methods

Market Restraints

High Level of Attrition within the Development Cycles Stringent Regulatory Framework Lack of Awareness of Immunotherapy

Opportunities

Developed Economies Showing Higher Development Rates

Key Topics Covered:

1. Introduction

2. Executive Summary

3. Immuno-oncology Therapy Market Market Dynamics

4. Global Immuno-oncology Therapy Market Competitive Landscape

5. Global Immuno-oncology Therapy Market Therapy Type Segment Analysis

6. Global Immuno-oncology Therapy Market Therapeutic Area Segment Analysis

7. Global Immuno-oncology Therapy Market End-User Segment Analysis

8. Global Immuno-oncology Therapy Market Regional Segment Analysis

9. Company Profiles

Amgen, Inc. AstraZeneca Plc. Bristol-Myers Squibb Company Eli Lilly and Company F.Hoffmann-La Roche Ltd. GlaxoSmithKline Plc. Janssen Biotech Merck and Co. Novartis AG Pfizer, Inc. Sanofi Spectrum Pharmaceuticals, Inc. Takeda Pharmaceuticals

For more information about this report visit https://www.researchandmarkets.com/research/3llcvh/immunooncology?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180516005955/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Hospital Management,Drug Discovery,Oncology Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH HOSPITALS ONCOLOGY PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 05/16/2018 10:52 AM/DISC: 05/16/2018 10:52 AM

http://www.businesswire.com/news/home/20180516005955/en